Private Equity
Vensana Capital, which was launched by healthcare-focused venture firm Versant Ventures, has closed its debut fund at US$225 million. Vensana Capital I's limited partners include public pensions, university endowments, foundations, academic health systems, family offices and fund-of-funds. The fund will invest in the medical tech sector. Versant's offices include San Diego, San Francisco, Minneapolis, New York City and Vancouver, British Columbia.
4 min read · 04 September 2019
Redwood City, California-based Bolt Biotherapeutics, a biotech firm focused on treating cancer, has named Dr. Randall Schatzman as CEO and a member of the board of directors. Previously, he was CEO of Alder BioPharmaceuticals Inc. Bolt's backers included Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences.
4 min read · 04 September 2019
2 min read · 04 September 2019
The past decade brought unprecedented change to venture capital. Today’s GP must bring together the sometimes competing goals of specialization, diversification and capitalization
6 min read · 03 September 2019
Xiang He Capital, a TMT-focused venture firm in China, has closed its second US-denominated fund at a hard cap of $425 million, beating its $350 million target. The fund's limited partners include global consultants, university endowments, foundations, family offices, pensions and fund-of-funds.
2 min read · 03 September 2019
DSG Consumer Partners has raised $65 million for its third fund, according to an SEC filing. Based in Mauritius and Singapore, DSG invests in consumer companies in India and Southeast Asia.
1 min read · 03 September 2019
Greenwave Opportunity Fund is seeking to raise $250 million. The fund will invest in, acquire and develop clean energy projects focusing on real estate, energy and water applications.
7 min read · 03 September 2019
4 min read · 03 September 2019
2 min read · 30 August 2019
Coefficient, F2 and Cultivation lead the way in last two weeks in August.
3 min read · 30 August 2019
